Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole with or without BYL719 or buparlisib in neoadjuvant HR-positive HER2-negative breast cancer
NL-OMON45221Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing BYL719 + letrozole, buparlisib + letrozole and placebo + letrozole (3 arms). Primary endpoints: Pathologic complete response based on tumor tissue and Objective response rate based on tumor tissue. Started Feb 2015; status: active, not recruiting.
02
Drugs
alpelisibbuparlisibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45221.